-
Mashup Score: 0
Phase 2 data support epcoritamab monotherapy as a promising chemotherapy-free option for older patients with newly diagnosed LBCL.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia. #leusm #ASH24 | @ASH_hematology https://t.co/P4J1jZnuCL
-
-
Mashup Score: 0Pirtobrutinib Triplet Improves MRD Outcomes in CLL - 9 hour(s) ago
Phase 2 results showed high undetectable MRD rates with pirtobrutinib, venetoclax, and obinutuzumab for patients with chronic lymphocytic leukemia.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Pirtobrutinib plus venetoclax and obinutuzumab produced a numerically higher rate of uMRD compared with previously reported data of ibrutinib and venetoclax for patients with CLL. #leusm #ASH24 | @ASH_hematology @NitinJainMD https://t.co/mR0hRcQKqA
-
-
Mashup Score: 0
Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Samatha Shenoy, NP, MSN, highlighted lifestyle recommendations to help patients who are receiving talquetamab treatment for multiple myeloma. #mmsm https://t.co/cwouwe2IZk
-
-
Mashup Score: 1
Panelists discuss how the symptoms of a patient with multiple myeloma led to their initial diagnosis and the progression of various treatments they underwent before becoming a candidate for CAR T therapy.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Panelists discuss how the symptoms of a patient with multiple myeloma led to their initial diagnosis and the progression of various treatments they underwent before becoming a candidate for CAR T therapy. #mmsm | @bhemato https://t.co/m90pfYTU45
-
-
Mashup Score: 0
Phase 3 data show meaningful benefits with uproleselan in patients with primary refractory AML and post-transplant survival.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The median OS for the ITT population was 13.0 months among those in the uproleselan arm vs 12.3 months in the placebo plus chemotherapy arm (HR, 0.89; 95% CI, 0.69-1.15). #leusm #ASH24 | @ASH_hematology https://t.co/2F7Xf5nM3w
-
-
Mashup Score: 1
The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
“Cladribine plus venetoclax is a highly effective curative regimen, producing deep and durable remissions in newly diagnosed MDS and AML,” Tapan M. Kadia, MD. #leusm #ASH24 | @ASH_hematology @TapKadia https://t.co/1FWXtdSZwO
-
-
Mashup Score: 0
For patients with CLL and SLL, sonrotoclax with zanubrutinib yielded high rates of overall response in the phase 1/1b BGB-11417-101 study.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Frontline treatment with sonrotoclax plus zanubrutinib elicited high responses with a tolerable safety profile patients with treatment-naïve CLL/SLL. #leusm #ASH24 | @ASH_hematology https://t.co/XxjlhqCKsy
-
-
Mashup Score: 0ESAs Yields Response in VEXAS Syndrome With or Without MDS - 1 day(s) ago
In patients with VEXAS Syndrome with or without MDS, ESAs/luspatercept generated positive hematologic improvement-erythroid responses.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
At week 16, hematologic improvement-erythroid was 38.8%, overall; 43.7% for no transfusion dependency; 25.6% for low transfusion dependency; and 23.0% for high transfusion dependency. #MDS #ASH24 | @ASH_hematology https://t.co/GszW26rduE
-
-
Mashup Score: 0
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists. #mmsm #ASH24 | @ASH_hematology @AlbanyMed https://t.co/Mpcj7LSa3F
-
“Epcoritamab monotherapy is a promising chemotherapy-free treatment option for older patients with comorbidities and newly diagnosed LBCL who are deemed ineligible for anthracycline-based regimens,” said Franck Morschhauser, MD, PhD. #lymsm #ASH24 https://t.co/fmcEyoCOvf